Non-Small-Cell Lung Cancer Drug Market Size, Trends and Insights By Cancer Type (Non-Small Cell Lung Cancer, Metastatic Lung Cancer, Pulmonary Neuroendocrine Tumours, Mediastina Tumours, Mesothelioma, Chest Wall Tumours), By Application (Adenocarcinomas, Squamous Cell Carcinoma, Large Cell Carcinomas, Others), By Molecule Type (Small Molecules, Biologics), By Drug Class (Alkylating Agents, Antimetabolites, EGFR Inhibitors, Mitotic Inhibitors, Multi-kinase Inhibitors, Others), By Treatment Type (Chemotherapy, Radiation Therapy, Targeted Therapy, Immunotherapy, Others), By Diagnosis (CT scan, X-Rays, Sputum Cytology, Bronchoscopy, Laboratory Tests, Thoracoscopy, Others), By End User (Hospitals, Homecare, Specialty Clinics, Others), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033
Report Snapshot
CAGR: 8.1%
| Study Period: | 2024-2033 |
| Fastest Growing Market: | Asia-Pacific |
| Largest Market: | Europe |
Major Players
- AstraZeneca PLC
- Bristol Myers Squibb Company
- Merck & Co. Inc.
- Hoffmann-La Roche Ltd.
- Pfizer Inc.
- Novartis AG
- Others
Reports Description
As per the current market research conducted by the CMI Team, the global Non-Small-Cell Lung Cancer Drug Market is expected to record a CAGR of 8.1% from 2024 to 2033. In 2024, the market size is projected to reach a valuation of USD 34,175.6 Million. By 2033, the valuation is anticipated to reach USD 68,888.6 Million.
The Non-Small-Cell Lung Cancer (NSCLC) drug market encompasses the development, manufacturing, and commercialization of pharmaceutical products aimed at treating NSCLC, the most common type of lung cancer. These drugs include targeted therapies, immunotherapies, chemotherapy agents, and supportive care medications.
With advancements in precision medicine and biomarker-driven approaches, the NSCLC drug market is witnessing a shift towards personalized treatment regimens tailored to individual patient profiles. The market is characterized by robust clinical research, regulatory approvals for novel therapeutics, and a focus on improving patient outcomes through innovative treatment modalities and multidisciplinary care approaches.
Non-Small-Cell Lung Cancer Drug Market – Significant Growth Factors
The Non-Small-Cell Lung Cancer Drug Market presents significant growth opportunities due to several factors:
- Advancements in Targeted Therapies: The development of targeted therapies, such as tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs), drives the NSCLC drug market. These therapies offer improved efficacy and tolerability compared to traditional chemotherapy, leading to increased adoption and market growth.
- Increasing Incidence of NSCLC: The rising prevalence of NSCLC, attributed to factors like smoking, air pollution, and aging populations, drive market demand for effective treatments. As the number of NSCLC cases continues to rise, the demand for NSCLC drugs also increases.
- Technological Innovations in Biomarker Testing: Technological advancements in biomarker testing facilitate personalized treatment approaches, allowing for the identification of specific molecular targets and the development of tailored therapies. The integration of biomarker-driven strategies into clinical practice drives market growth and innovation.
- Expanding Treatment Landscape: The emergence of novel treatment modalities, such as combination therapies, antibody-drug conjugates, and tumor-agnostic therapies, expands the treatment landscape for NSCLC. This diversification of treatment options offers new opportunities for patients and drives market growth.
- Development of Novel Therapeutics: The opportunity exists for pharmaceutical companies to develop novel therapeutics targeting specific molecular pathways and immune checkpoints implicated in NSCLC. Innovative approaches could lead to the discovery of breakthrough treatments with improved efficacy and safety profiles.
- Expansion into Emerging Markets: There is an opportunity for companies to expand their presence into emerging markets with growing healthcare infrastructure and increasing demand for NSCLC drugs. Access to these markets presents opportunities for revenue growth and market expansion, particularly in regions with high NSCLC incidence rates.
Non-Small-Cell Lung Cancer Drug Market – Mergers and Acquisitions
The Non-Small-Cell Lung Cancer Drug Market has seen several mergers and acquisitions in recent years, with companies seeking to expand their market presence and leverage synergies to improve their product offerings and profitability. Some notable examples of mergers and acquisitions in the Non-Small-Cell Lung Cancer Drug Market include:
- In 2022, Daiichi Sankyo obtained FDA approval for its drug for adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal (GEJ) adenocarcinoma. This approval marks a significant milestone in providing a new treatment option for this patient population.
- In 2022, The FDA granted accelerated approval to Mirati’s Krazati (adagrasib), a targeted therapy for adult patients with KRAS-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). This approval represents a significant advancement in precision medicine for NSCLC patients with specific genetic mutations.
- In 2022, Gilead and Dragonfly have announced a research collaboration to advance natural killer cell engagers in oncology. Gilead obtained a worldwide license from Dragonfly for their 5T4 targeting immunotherapy program DF7001 as part of the agreement.
These mergers and acquisitions have helped companies expand their product offerings, improve their market presence, and capitalize on growth opportunities in the Non-Small-Cell Lung Cancer Drug Market. The trend is expected to continue as companies seek to gain a competitive edge in the market.
COMPARATIVE ANALYSIS OF THE RELATED MARKET
| Non-Small-Cell Lung Cancer Drug Market | Bladder Cancer Market | Cancer Cachexia Market |
| CAGR 8.1% (Approx) | CAGR 5.2% (Approx) | CAGR 5.1% (Approx) |
| USS 68,888.6 Million by 2033 | USD 533.8 Million by 2033 | USD 5.1 Billion by 2033 |
Non-Small-Cell Lung Cancer Drug Market – Significant Threats
The Non-Small-Cell Lung Cancer Drug Market faces several significant threats that could impact its growth and profitability in the future. Some of these threats include:
- Development of Drug Resistance: The emergence of drug resistance poses a significant threat to NSCLC treatment efficacy. Tumor cells can develop resistance mechanisms against targeted therapies and immunotherapies, leading to treatment failure and disease progression.
- Stringent Regulatory Environment: Stringent regulatory requirements and lengthy approval processes for new NSCLC drugs can delay market entry and increase development costs. Regulatory hurdles may hinder innovation, limit treatment options, and delay patient access to potentially life-saving therapies.
- Competition from Biosimilars and Generics: The introduction of biosimilars and generic versions of established NSCLC drugs poses a threat to market share and profitability for originator companies. Competition from lower-cost alternatives may lead to pricing pressures and erosion of revenue for branded products.
- High Research and Development Costs: The high cost of research, development, and clinical trials for NSCLC drugs presents a financial challenge for pharmaceutical companies. Investment in drug discovery, preclinical studies, and large-scale clinical trials require substantial resources and carries financial risks, particularly if candidate drugs fail to achieve regulatory approval.
- Market Saturation and Pricing Pressures: Market saturation and pricing pressures in the NSCLC drug market can impact profitability and investment returns for companies. Intense competition among pharmaceutical manufacturers may lead to aggressive pricing strategies, reducing profit margins and hindering the development of innovative therapies.
Category-Wise Insights:
By Cancer Type
- Non-Small Cell Lung Cancer (NSCLC): The NSCLC drug market focuses on pharmaceuticals for treating NSCLC, the most common type of lung cancer. Trends include advancements in targeted therapies, immunotherapies, and personalized medicine approaches. Biomarker testing and combination therapies are gaining prominence, aiming to improve treatment outcomes and patient survival rates.
- Metastatic Lung Cancer: The metastatic lung cancer drug market addresses pharmaceuticals targeting lung cancer that has spread to distant sites. Trends involve the development of systemic therapies like chemotherapy, targeted therapy, and immunotherapy to manage metastatic disease. Personalized medicine approaches and clinical trial participation are increasing to explore novel treatment options.
- Pulmonary Neuroendocrine Tumours (PNETs): The pulmonary neuroendocrine tumor drug market addresses pharmaceuticals for treating PNETs, including typical and atypical carcinoids. Trends focus on the development of targeted therapies and somatostatin analogs to manage symptoms and slow tumor growth. Biomarker research and precision medicine approaches are emerging to improve treatment efficacy.
- Mediastinal Tumors: The mediastinal tumor drug market targets pharmaceuticals for treating tumors located in the mediastinum, such as thymomas and lymphomas. Trends involve the use of chemotherapy, radiation therapy, and targeted therapies to shrink tumors and improve patient outcomes. Advances in imaging technologies and multidisciplinary care approaches are enhancing treatment strategies.
- Mesothelioma: The mesothelioma drug market addresses pharmaceuticals for treating malignant mesothelioma, often caused by asbestos exposure. Trends include the development of multimodal treatment approaches combining surgery, chemotherapy, and immunotherapy to improve survival rates. Biomarker research and clinical trials are exploring novel therapeutic targets and treatment regimens.
- Chest Wall Tumors: The chest wall tumor drug market focuses on pharmaceuticals for treating tumors originating from the chest wall, including sarcomas and metastatic lesions. Trends involve the use of surgery, radiation therapy, and systemic therapies like chemotherapy and targeted therapy to manage tumor growth and alleviate symptoms. Advances in imaging technologies and minimally invasive surgical techniques are improving treatment outcomes.
By Application
- Adenocarcinomas: Adenocarcinomas are a type of NSCLC originating in the glandular cells of the lung. Trends in this segment include the development of targeted therapies such as EGFR inhibitors and ALK inhibitors, as well as immunotherapies tailored to specific molecular profiles associated with adenocarcinomas.
- Squamous Cell Carcinoma: Squamous cell carcinoma is another subtype of NSCLC, characterized by squamous epithelial cells in the lung. Trends include the investigation of targeted therapies like FGFR inhibitors and novel immunotherapies aimed at enhancing the treatment response in patients with squamous cell carcinoma.
- Large Cell Carcinomas: Large cell carcinomas represent a subset of NSCLC with poorly differentiated, large-sized tumor cells. Trends in this segment focus on the identification of actionable genetic mutations and the development of targeted therapies and immunotherapies tailored to the unique molecular characteristics of large cell carcinomas.
- Others: This category encompasses less common histological subtypes of NSCLC, such as Aden squamous carcinoma, bronchioloalveolar carcinoma, and sarcomatous carcinoma. Trends include efforts to elucidate the molecular underpinnings of these subtypes and develop targeted treatments specifically tailored to their genetic alterations and tumor biology.
By Drug Class
- Alkylating Agents: Alkylating agents interfere with DNA replication, leading to cell death. Trends include the development of newer agents with improved safety profiles and combination therapies to enhance efficacy and reduce resistance.
- Antimetabolites: Antimetabolites disrupt DNA and RNA synthesis, inhibiting cancer cell growth. Trends include the exploration of novel targets and combination regimens to overcome resistance and improve outcomes.
- EGFR Inhibitors: EGFR inhibitors target the epidermal growth factor receptor pathway, inhibiting cancer cell proliferation. Trends include the development of next-generation inhibitors and personalized treatment approaches based on biomarker status.
- Mitotic Inhibitors: Mitotic inhibitors disrupt cell division by targeting microtubules, leading to cell death. Trends include the investigation of new agents and combination therapies to enhance efficacy and minimize toxicity.
- Multi-kinase Inhibitors: Multi-kinase inhibitors target multiple signaling pathways involved in cancer growth and progression. Trends include the development of selective inhibitors with improved safety profiles and the exploration of combination regimens to overcome resistance.
- Others: This category may include immunotherapies, monoclonal antibodies, and other emerging treatments. Trends include the expansion of immunotherapy options, the development of novel targeted therapies, and the investigation of innovative treatment modalities such as tumor-agnostic therapies.
By Treatment Type
- Chemotherapy: Chemotherapy involves the use of cytotoxic drugs to kill cancer cells. While still a standard treatment for NSCLC, trends indicate a shift towards targeted therapies and immunotherapies due to their improved efficacy and tolerability, although chemotherapy remains an essential component of combination regimens, particularly in advanced stages.
- Radiation Therapy: Radiation therapy employs high-energy radiation to kill cancer cells. Trends include advancements in techniques such as intensity-modulated radiation therapy (IMRT) and stereotactic body radiation therapy (SBRT), offering improved tumor targeting and reduced toxicity. Combination with systemic therapies is increasingly explored for enhanced treatment outcomes.
- Targeted Therapy: Targeted therapy involves drugs that specifically target molecular abnormalities driving cancer growth. Trends include the development of tyrosine kinase inhibitors (TKIs) targeting EGFR, ALK, ROS1, and other mutations, as well as novel agents targeting emerging molecular targets, such as MET and RET alterations, to improve treatment options and outcomes.
- Immunotherapy: Immunotherapy harnesses the body’s immune system to fight cancer cells. Trends in NSCLC include the widespread adoption of immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 and CTLA-4 pathways, leading to durable responses in a subset of patients. Ongoing research focuses on combination strategies and biomarker-driven approaches to enhance immunotherapy efficacy.
- Others: Other treatments in the NSCLC drug market include angiogenesis inhibitors, antibody-drug conjugates, and cancer vaccines. Emerging trends involve the development of novel agents targeting alternative pathways involved in tumor progression and evasion of immune surveillance, aiming to expand treatment options and improve patient outcomes.
By Diagnosis
- CT scan: CT scans are widely used for diagnosing Non-Small-Cell Lung Cancer (NSCLC), providing detailed images of the lungs to detect tumors and assess their size, location, and spread. Trends include advancements in imaging technology, such as low-dose CT scans and contrast-enhanced imaging, to improve diagnostic accuracy and patient outcomes.
- X-rays: X-rays are a common diagnostic tool for detecting abnormalities in the lungs, including tumors associated with NSCLC. Trends include the integration of digital radiography and computer-aided detection systems to enhance sensitivity and specificity in detecting early-stage lung cancers and monitoring disease progression.
- Sputum Cytology: Sputum cytology involves examining sputum samples under a microscope to identify abnormal cells indicative of lung cancer, including NSCLC. Trends include the development of molecular testing techniques to improve the sensitivity and specificity of sputum cytology for early cancer detection and risk stratification.
- Bronchoscopy: Bronchoscopy is a minimally invasive procedure used to visualize the airways and obtain tissue samples for histological analysis in NSCLC diagnosis. Trends include the integration of advanced imaging technologies, such as narrow-band imaging and fluorescence bronchoscopy, to improve lesion detection and biopsy targeting accuracy.
- Laboratory Tests: Laboratory tests, including blood tests and molecular biomarker analysis, play a crucial role in NSCLC diagnosis and treatment decision-making. Trends include the development of liquid biopsy assays and next-generation sequencing platforms for detecting genetic mutations and predicting treatment response in NSCLC patients.
- Thoracoscopy: Thoracoscopy, or video-assisted thoracoscopic surgery (VATS), allows for minimally invasive biopsy and staging of NSCLC tumors. Trends include advancements in thoracoscopic instrumentation and techniques, such as robotic-assisted thoracic surgery, to improve surgical precision and patient outcomes while minimizing invasiveness and recovery time.
- Others: Other diagnostic modalities for NSCLC may include positron emission tomography (PET) scans, magnetic resonance imaging (MRI), and molecular imaging techniques. Trends include the integration of multimodal imaging approaches and artificial intelligence algorithms to enhance diagnostic accuracy and inform treatment decisions in NSCLC.
By End User
- Hospitals: Hospitals are primary providers of Non-Small-Cell Lung Cancer (NSCLC) drug treatments, offering comprehensive care services including chemotherapy, targeted therapy, and supportive care. Trends include the integration of multidisciplinary care teams, personalized treatment approaches, and advancements in surgical techniques such as minimally invasive procedures.
- Homecare: Homecare services provide NSCLC patients with supportive care, symptom management, and administration of oral medications in a home setting. Trends include the adoption of telemedicine for remote consultations, patient education programs, and the provision of home infusion therapy to enhance patient comfort and convenience.
- Specialty Clinics: Specialty clinics focus on NSCLC diagnosis, treatment, and management, offering specialized expertise and comprehensive care services. Trends include the integration of genomic testing and biomarker-driven treatment approaches, patient-centric care models, and collaboration with research institutions to advance clinical trials and therapeutic innovations.
- Others: Other end users in the NSCLC drug market may include ambulatory care centers, cancer treatment centers, and research institutes. These entities play diverse roles in NSCLC care, from providing outpatient chemotherapy and radiation therapy to conducting clinical trials and advancing scientific research to improve treatment outcomes.
Report Scope
| Feature of the Report | Details |
| Market Size in 2024 | USD 34,175.6 Million |
| Projected Market Size in 2033 | USD 68,888.6 Million |
| Market Size in 2023 | USD 31,614.8 Million |
| CAGR Growth Rate | 8.1% CAGR |
| Base Year | 2023 |
| Forecast Period | 2024-2033 |
| Key Segment | By Cancer Type, Application, Molecule Type, Drug Class, Treatment Type, Diagnosis, End User and Region |
| Report Coverage | Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends |
| Regional Scope | North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America |
| Buying Options | Request tailored purchasing options to fulfil your requirements for research. |
Non-Small-Cell Lung Cancer Drug Market – Regional Analysis
The Non-Small-Cell Lung Cancer Drug Market is segmented into various regions, including North America, Europe, Asia-Pacific, and LAMEA. Here is a brief overview of each region:
- North America: In North America, trends in the Non-Small-Cell Lung Cancer (NSCLC) drug market include a focus on precision medicine approaches, with the integration of biomarker testing and targeted therapies to tailor treatment regimens to individual patient profiles. Additionally, there is an emphasis on oncology research and development, with a high concentration of clinical trials and collaborations between academic institutions and pharmaceutical companies.
- Europe: In Europe, trends in the NSCLC drug market revolve around initiatives to improve patient access to innovative therapies and optimize healthcare delivery. This includes efforts to harmonize regulatory processes, facilitate early market access for promising treatments, and promote cost-effective utilization of healthcare resources through value-based pricing and reimbursement models.
- Asia-Pacific: In the Asia-Pacific region, trends in the NSCLC drug market are characterized by rising healthcare expenditures, increasing adoption of novel therapies, and expansion of healthcare infrastructure to address the growing burden of cancer. There is a focus on enhancing oncology care networks, fostering collaborations between healthcare stakeholders, and promoting innovation in drug development and delivery to meet the evolving needs of NSCLC patients.
- LAMEA (Latin America, Middle East & Africa): In LAMEA, trends in the NSCLC drug market are driven by efforts to address healthcare disparities and improve access to cancer care in underserved regions. This includes initiatives to strengthen healthcare systems, increase awareness about NSCLC prevention and early detection, and expand patient support services to enhance treatment outcomes and quality of life for NSCLC patients.
Competitive Landscape – Non-Small-Cell Lung Cancer Drug Market
The Non-Small-Cell Lung Cancer Drug Market is highly competitive, with a large number of manufacturers and retailers operating globally. Some of the key players in the market include:
- AstraZeneca PLC
- Bristol Myers Squibb Company
- Merck & Co. Inc.
- Hoffmann-La Roche Ltd.
- Pfizer Inc.
- Novartis AG
- Eli Lilly and Company
- Boehringer Ingelheim International GmbH
- Takeda Pharmaceutical Company Limited
- AbbVie Inc.
- GlaxoSmithKline plc
- Johnson & Johnson
- Sanofi S.A.
- Celgene Corporation
- Daiichi Sankyo Company Limited
- Others
These companies operate in the market through various strategies such as product innovation, mergers and acquisitions, and partnerships.
New players entering the Non-Small-Cell Lung Cancer (NSCLC) drug market, such as Mirati Therapeutics and Novocure, are adopting innovative approaches to address unmet medical needs. Mirati’s Krazati (adagrasib) targets specific genetic mutations, while Novocure’s Tumor Treating Fields (TTFields) offers a unique treatment modality.
Dominating the market are key players like AstraZeneca, Bristol Myers Squibb, and Merck & Co., leveraging extensive research, global reach, and robust product pipelines to offer a comprehensive portfolio of NSCLC drugs, consolidating their market position through continued innovation and strategic collaborations.
The Non-Small-Cell Lung Cancer Drug Market is segmented as follows:
By Cancer Type
- Non-Small Cell Lung Cancer
- Metastatic Lung Cancer
- Pulmonary Neuroendocrine Tumours
- Mediastina Tumours
- Mesothelioma
- Chest Wall Tumours
By Application
- Adenocarcinomas
- Squamous Cell Carcinoma
- Large Cell Carcinomas
- Others
By Molecule Type
- Small Molecules
- Biologics
By Drug Class
- Alkylating Agents
- Antimetabolites
- EGFR Inhibitors
- Mitotic Inhibitors
- Multi-kinase Inhibitors
- Others
By Treatment Type
- Chemotherapy
- Radiation Therapy
- Targeted Therapy
- Immunotherapy
- Others
By Diagnosis
- CT scan
- X-Rays
- Sputum Cytology
- Bronchoscopy
- Laboratory Tests
- Thoracoscopy
- Others
By End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Regional Coverage:
North America
- U.S.
- Canada
- Mexico
- Rest of North America
Europe
- Germany
- France
- U.K.
- Russia
- Italy
- Spain
- Netherlands
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Taiwan
- Rest of Asia Pacific
The Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of the Middle East & Africa
Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
- Chapter 1. Preface
- 1.1 Report Description and Scope
- 1.2 Research scope
- 1.3 Research methodology
- 1.3.1 Market Research Type
- 1.3.2 Market Research Methodology
- Chapter 2. Executive Summary
- 2.1 Global Non-Small-Cell Lung Cancer Drug Market, (2024 – 2033) (USD Million)
- 2.2 Global Non-Small-Cell Lung Cancer Drug Market: snapshot
- Chapter 3. Global Non-Small-Cell Lung Cancer Drug Market – Industry Analysis
- 3.1 Non-Small-Cell Lung Cancer Drug Market: Market Dynamics
- 3.2 Market Drivers
- 3.2.1 Advancements in Targeted Therapies
- 3.2.2 Increasing Incidence of NSCLC
- 3.2.3 Technological Innovations in Biomarker Testing
- 3.2.4 Expanding Treatment Landscape
- 3.2.5 Development of Novel Therapeutics
- 3.2.6 Expansion into Emerging Markets.
- 3.3 Market Restraints
- 3.4 Market Opportunities
- 3.5 Market Challenges
- 3.6 Porter’s Five Forces Analysis
- 3.7 Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Cancer Type
- 3.7.2 Market Attractiveness Analysis By Application
- 3.7.3 Market Attractiveness Analysis By Molecule Type
- 3.7.4 Market Attractiveness Analysis By Drug Class
- 3.7.5 Market Attractiveness Analysis By Treatment Type
- 3.7.6 Market Attractiveness Analysis By Diagnosis
- 3.7.7 Market Attractiveness Analysis By End User
- Chapter 4. Global Non-Small-Cell Lung Cancer Drug Market- Competitive Landscape
- 4.1 Company market share analysis
- 4.1.1 Global Non-Small-Cell Lung Cancer Drug Market: Company Market Share, 2023
- 4.2 Strategic development
- 4.2.1 Acquisitions & mergers
- 4.2.2 New Product launches
- 4.2.3 Agreements, partnerships, cullaborations, and joint ventures
- 4.2.4 Research and development and Regional expansion
- 4.3 Price trend analysis
- 4.1 Company market share analysis
- Chapter 5. Global Non-Small-Cell Lung Cancer Drug Market – Cancer Type Analysis
- 5.1 Global Non-Small-Cell Lung Cancer Drug Market Overview: By Cancer Type
- 5.1.1 Global Non-Small-Cell Lung Cancer Drug Market Share, By Cancer Type, 2023 and 2033
- 5.2 Non-Small Cell Lung Cancer
- 5.2.1 Global Non-Small-Cell Lung Cancer Drug Market by Non-Small Cell Lung Cancer, 2024 – 2033 (USD Million)
- 5.3 Metastatic Lung Cancer
- 5.3.1 Global Non-Small-Cell Lung Cancer Drug Market by Metastatic Lung Cancer, 2024 – 2033 (USD Million)
- 5.4 Pulmonary Neuroendocrine Tumours
- 5.4.1 Global Non-Small-Cell Lung Cancer Drug Market by Pulmonary Neuroendocrine Tumours, 2024 – 2033 (USD Million)
- 5.5 Mediastina Tumours
- 5.5.1 Global Non-Small-Cell Lung Cancer Drug Market by Mediastina Tumours, 2024 – 2033 (USD Million)
- 5.6 Mesothelioma
- 5.6.1 Global Non-Small-Cell Lung Cancer Drug Market by Mesothelioma, 2024 – 2033 (USD Million)
- 5.7 Chest Wall Tumours
- 5.7.1 Global Non-Small-Cell Lung Cancer Drug Market by Chest Wall Tumours, 2024 – 2033 (USD Million)
- 5.1 Global Non-Small-Cell Lung Cancer Drug Market Overview: By Cancer Type
- Chapter 6. Global Non-Small-Cell Lung Cancer Drug Market – Application Analysis
- 6.1 Global Non-Small-Cell Lung Cancer Drug Market Overview: By Application
- 6.1.1 Global Non-Small-Cell Lung Cancer Drug Market Share, By Application, 2023 and 2033
- 6.2 Adenocarcinomas
- 6.2.1 Global Non-Small-Cell Lung Cancer Drug Market by Adenocarcinomas, 2024 – 2033 (USD Million)
- 6.3 Squamous Cell Carcinoma
- 6.3.1 Global Non-Small-Cell Lung Cancer Drug Market by Squamous Cell Carcinoma, 2024 – 2033 (USD Million)
- 6.4 Large Cell Carcinomas
- 6.4.1 Global Non-Small-Cell Lung Cancer Drug Market by Large Cell Carcinomas, 2024 – 2033 (USD Million)
- 6.5 Others
- 6.5.1 Global Non-Small-Cell Lung Cancer Drug Market by Others, 2024 – 2033 (USD Million)
- 6.1 Global Non-Small-Cell Lung Cancer Drug Market Overview: By Application
- Chapter 7. Global Non-Small-Cell Lung Cancer Drug Market – Molecule Type Analysis
- 7.1 Global Non-Small-Cell Lung Cancer Drug Market Overview: By Molecule Type
- 7.1.1 Global Non-Small-Cell Lung Cancer Drug Market Share, By Molecule Type, 2023 and 2033
- 7.2 Small Molecules
- 7.2.1 Global Non-Small-Cell Lung Cancer Drug Market by Small Molecules, 2024 – 2033 (USD Million)
- 7.3 Biologics
- 7.3.1 Global Non-Small-Cell Lung Cancer Drug Market by Biologics, 2024 – 2033 (USD Million)
- 7.1 Global Non-Small-Cell Lung Cancer Drug Market Overview: By Molecule Type
- Chapter 8. Global Non-Small-Cell Lung Cancer Drug Market – Drug Class Analysis
- 8.1 Global Non-Small-Cell Lung Cancer Drug Market Overview: By Drug Class
- 8.1.1 Global Non-Small-Cell Lung Cancer Drug Market Share, By Drug Class, 2023 and 2033
- 8.2 Alkylating Agents
- 8.2.1 Global Non-Small-Cell Lung Cancer Drug Market by Alkylating Agents, 2024 – 2033 (USD Million)
- 8.3 Antimetabolites
- 8.3.1 Global Non-Small-Cell Lung Cancer Drug Market by Antimetabolites, 2024 – 2033 (USD Million)
- 8.4 EGFR Inhibitors
- 8.4.1 Global Non-Small-Cell Lung Cancer Drug Market by EGFR Inhibitors, 2024 – 2033 (USD Million)
- 8.5 Mitotic Inhibitors
- 8.5.1 Global Non-Small-Cell Lung Cancer Drug Market by Mitotic Inhibitors, 2024 – 2033 (USD Million)
- 8.6 Multi-kinase Inhibitors
- 8.6.1 Global Non-Small-Cell Lung Cancer Drug Market by Multi-kinase Inhibitors, 2024 – 2033 (USD Million)
- 8.7 Others
- 8.7.1 Global Non-Small-Cell Lung Cancer Drug Market by Others, 2024 – 2033 (USD Million)
- 8.1 Global Non-Small-Cell Lung Cancer Drug Market Overview: By Drug Class
- Chapter 9. Global Non-Small-Cell Lung Cancer Drug Market – Treatment Type Analysis
- 9.1 Global Non-Small-Cell Lung Cancer Drug Market Overview: By Treatment Type
- 9.1.1 Global Non-Small-Cell Lung Cancer Drug Market Share, By Treatment Type, 2023 and 2033
- 9.2 Chemotherapy
- 9.2.1 Global Non-Small-Cell Lung Cancer Drug Market by Chemotherapy, 2024 – 2033 (USD Million)
- 9.3 Radiation Therapy
- 9.3.1 Global Non-Small-Cell Lung Cancer Drug Market by Radiation Therapy, 2024 – 2033 (USD Million)
- 9.4 Targeted Therapy
- 9.4.1 Global Non-Small-Cell Lung Cancer Drug Market by Targeted Therapy, 2024 – 2033 (USD Million)
- 9.5 Immunotherapy
- 9.5.1 Global Non-Small-Cell Lung Cancer Drug Market by Immunotherapy, 2024 – 2033 (USD Million)
- 9.6 Others
- 9.6.1 Global Non-Small-Cell Lung Cancer Drug Market by Others, 2024 – 2033 (USD Million)
- 9.1 Global Non-Small-Cell Lung Cancer Drug Market Overview: By Treatment Type
- Chapter 10. Global Non-Small-Cell Lung Cancer Drug Market – Diagnosis Analysis
- 10.1 Global Non-Small-Cell Lung Cancer Drug Market Overview: By Diagnosis
- 10.1.1 Global Non-Small-Cell Lung Cancer Drug Market Share, By Diagnosis, 2023 and 2033
- 10.2 CT scan
- 10.2.1 Global Non-Small-Cell Lung Cancer Drug Market by CT Scan, 2024 – 2033 (USD Million)
- 10.3 X-Rays
- 10.3.1 Global Non-Small-Cell Lung Cancer Drug Market by X-Rays, 2024 – 2033 (USD Million)
- 10.4 Sputum Cytology
- 10.4.1 Global Non-Small-Cell Lung Cancer Drug Market by Sputum Cytology, 2024 – 2033 (USD Million)
- 10.5 Bronchoscopy
- 10.5.1 Global Non-Small-Cell Lung Cancer Drug Market by Bronchoscopy, 2024 – 2033 (USD Million)
- 10.6 Laboratory Tests
- 10.6.1 Global Non-Small-Cell Lung Cancer Drug Market by Laboratory Tests, 2024 – 2033 (USD Million)
- 10.7 Thoracoscopy
- 10.7.1 Global Non-Small-Cell Lung Cancer Drug Market by Thoracoscopy, 2024 – 2033 (USD Million)
- 10.8 Others
- 10.8.1 Global Non-Small-Cell Lung Cancer Drug Market by Others, 2024 – 2033 (USD Million)
- 10.1 Global Non-Small-Cell Lung Cancer Drug Market Overview: By Diagnosis
- Chapter 11. Global Non-Small-Cell Lung Cancer Drug Market – End User Analysis
- 11.1 Global Non-Small-Cell Lung Cancer Drug Market Overview: By End User
- 11.1.1 Global Non-Small-Cell Lung Cancer Drug Market Share, By End User, 2023 and 2033
- 11.2 Hospitals
- 11.2.1 Global Non-Small-Cell Lung Cancer Drug Market by Hospitals, 2024 – 2033 (USD Million)
- 11.3 Homecare
- 11.3.1 Global Non-Small-Cell Lung Cancer Drug Market by Homecare, 2024 – 2033 (USD Million)
- 11.4 Specialty Clinics
- 11.4.1 Global Non-Small-Cell Lung Cancer Drug Market by Specialty Clinics, 2024 – 2033 (USD Million)
- 11.5 Others
- 11.5.1 Global Non-Small-Cell Lung Cancer Drug Market by Others, 2024 – 2033 (USD Million)
- 11.1 Global Non-Small-Cell Lung Cancer Drug Market Overview: By End User
- Chapter 12. Non-Small-Cell Lung Cancer Drug Market – Regional Analysis
- 12.1 Global Non-Small-Cell Lung Cancer Drug Market Regional Overview
- 12.2 Global Non-Small-Cell Lung Cancer Drug Market Share, by Region, 2023 & 2033 (USD Million)
- 12.3. North America
- 12.3.1 North America Non-Small-Cell Lung Cancer Drug Market, 2024 – 2033 (USD Million)
- 12.3.1.1 North America Non-Small-Cell Lung Cancer Drug Market, by Country, 2024 – 2033 (USD Million)
- 12.3.1 North America Non-Small-Cell Lung Cancer Drug Market, 2024 – 2033 (USD Million)
- 12.4 North America Non-Small-Cell Lung Cancer Drug Market, by Cancer Type, 2024 – 2033
- 12.4.1 North America Non-Small-Cell Lung Cancer Drug Market, by Cancer Type, 2024 – 2033 (USD Million)
- 12.5 North America Non-Small-Cell Lung Cancer Drug Market, by Application, 2024 – 2033
- 12.5.1 North America Non-Small-Cell Lung Cancer Drug Market, by Application, 2024 – 2033 (USD Million)
- 12.6 North America Non-Small-Cell Lung Cancer Drug Market, by Molecule Type, 2024 – 2033
- 12.6.1 North America Non-Small-Cell Lung Cancer Drug Market, by Molecule Type, 2024 – 2033 (USD Million)
- 12.7 North America Non-Small-Cell Lung Cancer Drug Market, by Drug Class, 2024 – 2033
- 12.7.1 North America Non-Small-Cell Lung Cancer Drug Market, by Drug Class, 2024 – 2033 (USD Million)
- 12.8 North America Non-Small-Cell Lung Cancer Drug Market, by Treatment Type, 2024 – 2033
- 12.8.1 North America Non-Small-Cell Lung Cancer Drug Market, by Treatment Type, 2024 – 2033 (USD Million)
- 12.9 North America Non-Small-Cell Lung Cancer Drug Market, by Diagnosis, 2024 – 2033
- 12.9.1 North America Non-Small-Cell Lung Cancer Drug Market, by Diagnosis, 2024 – 2033 (USD Million)
- 12.10 North America Non-Small-Cell Lung Cancer Drug Market, by End User, 2024 – 2033
- 12.10.1 North America Non-Small-Cell Lung Cancer Drug Market, by End User, 2024 – 2033 (USD Million)
- 12.11. Europe
- 12.11.1 Europe Non-Small-Cell Lung Cancer Drug Market, 2024 – 2033 (USD Million)
- 12.11.1.1 Europe Non-Small-Cell Lung Cancer Drug Market, by Country, 2024 – 2033 (USD Million)
- 12.11.1 Europe Non-Small-Cell Lung Cancer Drug Market, 2024 – 2033 (USD Million)
- 12.12 Europe Non-Small-Cell Lung Cancer Drug Market, by Cancer Type, 2024 – 2033
- 12.12.1 Europe Non-Small-Cell Lung Cancer Drug Market, by Cancer Type, 2024 – 2033 (USD Million)
- 12.13 Europe Non-Small-Cell Lung Cancer Drug Market, by Application, 2024 – 2033
- 12.13.1 Europe Non-Small-Cell Lung Cancer Drug Market, by Application, 2024 – 2033 (USD Million)
- 12.14 Europe Non-Small-Cell Lung Cancer Drug Market, by Molecule Type, 2024 – 2033
- 12.14.1 Europe Non-Small-Cell Lung Cancer Drug Market, by Molecule Type, 2024 – 2033 (USD Million)
- 12.15 Europe Non-Small-Cell Lung Cancer Drug Market, by Drug Class, 2024 – 2033
- 12.15.1 Europe Non-Small-Cell Lung Cancer Drug Market, by Drug Class, 2024 – 2033 (USD Million)
- 12.16 Europe Non-Small-Cell Lung Cancer Drug Market, by Treatment Type, 2024 – 2033
- 12.16.1 Europe Non-Small-Cell Lung Cancer Drug Market, by Treatment Type, 2024 – 2033 (USD Million)
- 12.17 Europe Non-Small-Cell Lung Cancer Drug Market, by Diagnosis, 2024 – 2033
- 12.17.1 Europe Non-Small-Cell Lung Cancer Drug Market, by Diagnosis, 2024 – 2033 (USD Million)
- 12.18 Europe Non-Small-Cell Lung Cancer Drug Market, by End User, 2024 – 2033
- 12.18.1 Europe Non-Small-Cell Lung Cancer Drug Market, by End User, 2024 – 2033 (USD Million)
- 12.19. Asia Pacific
- 12.19.1 Asia Pacific Non-Small-Cell Lung Cancer Drug Market, 2024 – 2033 (USD Million)
- 12.19.1.1 Asia Pacific Non-Small-Cell Lung Cancer Drug Market, by Country, 2024 – 2033 (USD Million)
- 12.19.1 Asia Pacific Non-Small-Cell Lung Cancer Drug Market, 2024 – 2033 (USD Million)
- 12.20 Asia Pacific Non-Small-Cell Lung Cancer Drug Market, by Cancer Type, 2024 – 2033
- 12.20.1 Asia Pacific Non-Small-Cell Lung Cancer Drug Market, by Cancer Type, 2024 – 2033 (USD Million)
- 12.21 Asia Pacific Non-Small-Cell Lung Cancer Drug Market, by Application, 2024 – 2033
- 12.21.1 Asia Pacific Non-Small-Cell Lung Cancer Drug Market, by Application, 2024 – 2033 (USD Million)
- 12.22 Asia Pacific Non-Small-Cell Lung Cancer Drug Market, by Molecule Type, 2024 – 2033
- 12.22.1 Asia Pacific Non-Small-Cell Lung Cancer Drug Market, by Molecule Type, 2024 – 2033 (USD Million)
- 12.23 Asia Pacific Non-Small-Cell Lung Cancer Drug Market, by Drug Class, 2024 – 2033
- 12.23.1 Asia Pacific Non-Small-Cell Lung Cancer Drug Market, by Drug Class , 2024 – 2033 (USD Million)
- 12.24 Asia Pacific Non-Small-Cell Lung Cancer Drug Market, by Treatment Type, 2024 – 2033
- 12.24.1 Asia Pacific Non-Small-Cell Lung Cancer Drug Market, by Treatment Type, 2024 – 2033 (USD Million)
- 12.25 Asia Pacific Non-Small-Cell Lung Cancer Drug Market, by Diagnosis, 2024 – 2033
- 12.25.1 Asia Pacific Non-Small-Cell Lung Cancer Drug Market, by Diagnosis, 2024 – 2033 (USD Million)
- 12.26 Asia Pacific Non-Small-Cell Lung Cancer Drug Market, by End User, 2024 – 2033
- 12.26.1 Asia Pacific Non-Small-Cell Lung Cancer Drug Market, by End User, 2024 – 2033 (USD Million)
- 12.27. Latin America
- 12.27.1 Latin America Non-Small-Cell Lung Cancer Drug Market, 2024 – 2033 (USD Million)
- 12.27.1.1 Latin America Non-Small-Cell Lung Cancer Drug Market, by Country, 2024 – 2033 (USD Million)
- 12.27.1 Latin America Non-Small-Cell Lung Cancer Drug Market, 2024 – 2033 (USD Million)
- 12.28 Latin America Non-Small-Cell Lung Cancer Drug Market, by Cancer Type, 2024 – 2033
- 12.28.1 Latin America Non-Small-Cell Lung Cancer Drug Market, by Cancer Type, 2024 – 2033 (USD Million)
- 12.29 Latin America Non-Small-Cell Lung Cancer Drug Market, by Application, 2024 – 2033
- 12.29.1 Latin America Non-Small-Cell Lung Cancer Drug Market, by Application, 2024 – 2033 (USD Million)
- 12.30 Latin America Non-Small-Cell Lung Cancer Drug Market, by Molecule Type , 2024 – 2033
- 12.30.1 Latin America Non-Small-Cell Lung Cancer Drug Market, by Molecule Type , 2024 – 2033 (USD Million)
- 12.31 Latin America Non-Small-Cell Lung Cancer Drug Market, by Drug Class , 2024 – 2033
- 12.31.1 Latin America Non-Small-Cell Lung Cancer Drug Market, by Drug Class, 2024 – 2033 (USD Million)
- 12.32 Latin America Non-Small-Cell Lung Cancer Drug Market, by Treatment Type, 2024 – 2033
- 12.32.1 Latin America Non-Small-Cell Lung Cancer Drug Market, by Treatment Type, 2024 – 2033 (USD Million)
- 12.33 Latin America Non-Small-Cell Lung Cancer Drug Market, by Diagnosis, 2024 – 2033
- 12.33.1 Latin America Non-Small-Cell Lung Cancer Drug Market, by Diagnosis, 2024 – 2033 (USD Million)
- 12.34 Latin America Non-Small-Cell Lung Cancer Drug Market, by End User, 2024 – 2033
- 12.34.1 Latin America Non-Small-Cell Lung Cancer Drug Market, by End User, 2024 – 2033 (USD Million)
- 12.35. The Middle-East and Africa
- 12.35.1 The Middle-East and Africa Non-Small-Cell Lung Cancer Drug Market, 2024 – 2033 (USD Million)
- 12.35.1.1 The Middle-East and Africa Non-Small-Cell Lung Cancer Drug Market, by Country, 2024 – 2033 (USD Million)
- 12.35.1 The Middle-East and Africa Non-Small-Cell Lung Cancer Drug Market, 2024 – 2033 (USD Million)
- 12.36 The Middle-East and Africa Non-Small-Cell Lung Cancer Drug Market, by Cancer Type, 2024 – 2033
- 12.36.1 The Middle-East and Africa Non-Small-Cell Lung Cancer Drug Market, by Cancer Type, 2024 – 2033 (USD Million)
- 12.37 The Middle-East and Africa Non-Small-Cell Lung Cancer Drug Market, by Application, 2024 – 2033
- 12.37.1 The Middle-East and Africa Non-Small-Cell Lung Cancer Drug Market, by Application, 2024 – 2033 (USD Million)
- 12.38 The Middle-East and Africa Non-Small-Cell Lung Cancer Drug Market, by Molecule Type, 2024 – 2033
- 12.38.1 The Middle-East and Africa Non-Small-Cell Lung Cancer Drug Market, by Molecule Type , 2024 – 2033 (USD Million)
- 12.39 The Middle-East and Africa Non-Small-Cell Lung Cancer Drug Market, by Drug Class, 2024 – 2033
- 12.39.1 The Middle-East and Africa Non-Small-Cell Lung Cancer Drug Market, by Drug Class, 2024 – 2033 (USD Million)
- 12.40 The Middle-East and Africa Non-Small-Cell Lung Cancer Drug Market, by Treatment Type, 2024 – 2033
- 12.40.1 The Middle-East and Africa Non-Small-Cell Lung Cancer Drug Market, by Treatment Type, 2024 – 2033 (USD Million)
- 12.41 The Middle-East and Africa Non-Small-Cell Lung Cancer Drug Market, by Diagnosis , 2024 – 2033
- 12.41.1 The Middle-East and Africa Non-Small-Cell Lung Cancer Drug Market, by Diagnosis, 2024 – 2033 (USD Million)
- 12.42 The Middle-East and Africa Non-Small-Cell Lung Cancer Drug Market, by End User, 2024 – 2033
- 12.42.1 The Middle-East and Africa Non-Small-Cell Lung Cancer Drug Market, by End User, 2024 – 2033 (USD Million)
- Chapter 13. Company Profiles
- 13.1 AstraZeneca PLC
- 13.1.1 Overview
- 13.1.2 Financials
- 13.1.3 Product Portfolio
- 13.1.4 Business Strategy
- 13.1.5 Recent Developments
- 13.2 Bristol Myers Squibb Company
- 13.2.1 Overview
- 13.2.2 Financials
- 13.2.3 Product Portfolio
- 13.2.4 Business Strategy
- 13.2.5 Recent Developments
- 13.3 Merck & Co. Inc.
- 13.3.1 Overview
- 13.3.2 Financials
- 13.3.3 Product Portfolio
- 13.3.4 Business Strategy
- 13.3.5 Recent Developments
- 13.4 F. Hoffmann-La Roche Ltd.
- 13.4.1 Overview
- 13.4.2 Financials
- 13.4.3 Product Portfolio
- 13.4.4 Business Strategy
- 13.4.5 Recent Developments
- 13.5 Pfizer Inc.
- 13.5.1 Overview
- 13.5.2 Financials
- 13.5.3 Product Portfolio
- 13.5.4 Business Strategy
- 13.5.5 Recent Developments
- 13.6 Novartis AG
- 13.6.1 Overview
- 13.6.2 Financials
- 13.6.3 Product Portfolio
- 13.6.4 Business Strategy
- 13.6.5 Recent Developments
- 13.7 Eli Lilly and Company
- 13.7.1 Overview
- 13.7.2 Financials
- 13.7.3 Product Portfolio
- 13.7.4 Business Strategy
- 13.7.5 Recent Developments
- 13.8 Boehringer Ingelheim International GmbH
- 13.8.1 Overview
- 13.8.2 Financials
- 13.8.3 Product Portfolio
- 13.8.4 Business Strategy
- 13.8.5 Recent Developments
- 13.9 Takeda Pharmaceutical Company Limited
- 13.9.1 Overview
- 13.9.2 Financials
- 13.9.3 Product Portfolio
- 13.9.4 Business Strategy
- 13.9.5 Recent Developments
- 13.10 AbbVie Inc.
- 13.10.1 Overview
- 13.10.2 Financials
- 13.10.3 Product Portfolio
- 13.10.4 Business Strategy
- 13.10.5 Recent Developments
- 13.11 GlaxoSmithKline plc
- 13.11.1 Overview
- 13.11.2 Financials
- 13.11.3 Product Portfolio
- 13.11.4 Business Strategy
- 13.11.5 Recent Developments
- 13.12 Johnson & Johnson
- 13.12.1 Overview
- 13.12.2 Financials
- 13.12.3 Product Portfolio
- 13.12.4 Business Strategy
- 13.12.5 Recent Developments
- 13.13 Sanofi S.A.
- 13.13.1 Overview
- 13.13.2 Financials
- 13.13.3 Product Portfolio
- 13.13.4 Business Strategy
- 13.13.5 Recent Developments
- 13.14 Celgene Corporation
- 13.14.1 Overview
- 13.14.2 Financials
- 13.14.3 Product Portfolio
- 13.14.4 Business Strategy
- 13.14.5 Recent Developments
- 13.15 Daiichi Sankyo Company Limited
- 13.15.1 Overview
- 13.15.2 Financials
- 13.15.3 Product Portfolio
- 13.15.4 Business Strategy
- 13.15.5 Recent Developments
- 13.16 Others.
- 13.16.1 Overview
- 13.16.2 Financials
- 13.16.3 Product Portfolio
- 13.16.4 Business Strategy
- 13.16.5 Recent Developments
- 13.1 AstraZeneca PLC
List Of Figures
Figures No 1 to 58
List Of Tables
Tables No 1 to 177
Report Methodology
To get the most precise estimates and forecasts possible, Custom Market Insights applies a detailed and adaptive research methodology centered on reducing deviations. For segregating and assessing quantitative aspects of the market, the company uses a combination of top-down and bottom-up approaches. Furthermore, data triangulation, which examines the market from three different aspects, is a recurring theme in all of our research reports. The following are critical components of the methodology used in all of our studies:
Preliminary Data Mining
On a broad scale, raw market information is retrieved and compiled. Data is constantly screened to make sure that only substantiated and verified sources are taken into account. Furthermore, data is mined from a plethora of reports in our archive and also several reputed & reliable paid databases. To gain a detailed understanding of the business, it is necessary to know the entire product life cycle and to facilitate this, we gather data from different suppliers, distributors, and buyers.
Surveys, technological conferences, and trade magazines are used to identify technical issues and trends. Technical data is also gathered from the standpoint of intellectual property, with a focus on freedom of movement and white space. The dynamics of the industry in terms of drivers, restraints, and valuation trends are also gathered. As a result, the content created contains a diverse range of original data, which is then cross-validated and verified with published sources.
Statistical Model
Simulation models are used to generate our business estimates and forecasts. For each study, a one-of-a-kind model is created. Data gathered for market dynamics, the digital landscape, development services, and valuation patterns are fed into the prototype and analyzed concurrently. These factors are compared, and their effect over the projected timeline is quantified using correlation, regression, and statistical modeling. Market forecasting is accomplished through the use of a combination of economic techniques, technical analysis, industry experience, and domain knowledge.
Short-term forecasting is typically done with econometric models, while long-term forecasting is done with technological market models. These are based on a synthesis of the technological environment, legal frameworks, economic outlook, and business regulations. Bottom-up market evaluation is favored, with crucial regional markets reviewed as distinct entities and data integration to acquire worldwide estimates. This is essential for gaining a thorough knowledge of the industry and ensuring that errors are kept to a minimum.
Some of the variables taken into account for forecasting are as follows:
• Industry drivers and constraints, as well as their current and projected impact
• The raw material case, as well as supply-versus-price trends
• Current volume and projected volume growth through 2033
We allocate weights to these variables and use weighted average analysis to determine the estimated market growth rate.
Primary Validation
This is the final step in our report’s estimating and forecasting process. Extensive primary interviews are carried out, both in-person and over the phone, to validate our findings and the assumptions that led to them.
Leading companies from across the supply chain, including suppliers, technology companies, subject matter experts, and buyers, use techniques like interviewing to ensure a comprehensive and non-biased overview of the business. These interviews are conducted all over the world, with the help of local staff and translators, to overcome language barriers.
Primary interviews not only aid with data validation, but also offer additional important insight into the industry, existing business scenario, and future projections, thereby improving the quality of our reports.
All of our estimates and forecasts are validated through extensive research work with key industry participants (KIPs), which typically include:
• Market leaders
• Suppliers of raw materials
• Suppliers of raw materials
• Buyers.
The following are the primary research objectives:
• To ensure the accuracy and acceptability of our data.
• Gaining an understanding of the current market and future projections.
Data Collection Matrix
| Perspective | Primary research | Secondary research |
| Supply-side |
|
|
| Demand-side |
|
|
Market Analysis Matrix
| Qualitative analysis | Quantitative analysis |
|
|
Prominent Player
- AstraZeneca PLC
- Bristol Myers Squibb Company
- Merck & Co. Inc.
- Hoffmann-La Roche Ltd.
- Pfizer Inc.
- Novartis AG
- Eli Lilly and Company
- Boehringer Ingelheim International GmbH
- Takeda Pharmaceutical Company Limited
- AbbVie Inc.
- GlaxoSmithKline plc
- Johnson & Johnson
- Sanofi S.A.
- Celgene Corporation
- Daiichi Sankyo Company Limited
- Others
FAQs
The key factors driving the Market are Advancements in Targeted Therapies, Increasing Incidence of NSCLC, Technological Innovations in Biomarker Testing, Expanding Treatment Landscape, Development of Novel Therapeutics, Expansion into Emerging Markets.
The “Adenocarcinomas” had the largest share in the global market for Non-Small-Cell Lung Cancer Drug.
The “Alkylating Agents” category dominated the market in 2023.
The key players in the market are AstraZeneca PLC, Bristol Myers Squibb Company, Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Pfizer Inc., Novartis AG, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Takeda Pharmaceutical Company Limited, AbbVie Inc., GlaxoSmithKline plc, Johnson & Johnson, Sanofi S.A., Celgene Corporation, Daiichi Sankyo Company Limited, Others.
“North America” had the largest share in the Non-Small-Cell Lung Cancer Drug Market.
The global market is projected to grow at a CAGR of 8.1% during the forecast period, 2024-2033.
The Non-Small-Cell Lung Cancer Drug Market size was valued at USD 34,175.6 Million in 2024.